Qube Research & Technologies LTD Tg Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

  • $65.7 Billion
  • Q3 2024

A detailed history of Qube Research & Technologies LTD transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 371,841 shares of TGTX stock, worth $11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
371,841
Holding current value
$11 Million
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$17.21 - $25.28 $6.4 Million - $9.4 Million
371,841 New
371,841 $8.7 Million
Q1 2024

May 14, 2024
BUY
$13.02 - $21.3 $1.4 Million - $2.29 Million
107,363 New
107,363 $1.63 Million
Q4 2022

Feb 14, 2023
BUY
$5.01 - $11.83 $301,632 - $712,236
60,206 Added 38.76%
215,527 $2.55 Million
Q3 2022

Nov 14, 2022
SELL
$4.57 - $8.4 $309,695 - $569,242
-67,767 Reduced 30.38%
155,321 $920,000
Q2 2022

Aug 15, 2022
BUY
$3.74 - $10.66 $834,349 - $2.38 Million
223,088 New
223,088 $948,000
Q3 2021

Nov 12, 2021
SELL
$21.78 - $40.45 $510,479 - $948,067
-23,438 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$32.5 - $48.96 $761,735 - $1.15 Million
23,438 New
23,438 $909,000
Q3 2020

Nov 12, 2020
SELL
$18.49 - $27.24 $321,966 - $474,330
-17,413 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$8.9 - $21.84 $154,975 - $380,299
17,413 New
17,413 $339,000
Q1 2020

May 15, 2020
SELL
$7.14 - $15.99 $164,898 - $369,289
-23,095 Closed
0 $0
Q4 2019

Feb 13, 2020
BUY
$5.1 - $11.2 $117,784 - $258,663
23,095 New
23,095 $256,000

Others Institutions Holding TGTX

# of Institutions
338
Shares Held
88.3M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email